NCT01668173终止2 期
A Phase II Study of the HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Overall Objective Response
研究概览
简要总结
The purpose of this study is to test a new drug called AUY922. AUY922 is not FDA-approved. AUY922 is a new kind of drug that attacks a protein called HSP90. HSP90 is found in both normal and cancer cells, but the investigators think it is more important in cancer cells.
This study will see if AUY922 helps people with myelofibrosis, essential thrombocythemia and polycythemia vera. This study will also see if AUY922 is safe in people with myelofibrosis, essential thrombocythemia and polycythemia vera. It will find out what effects, good and/or bad, AUY922 has on the patient and the disease. The researchers hope that this study will help them to find better treatments for primary myelofibrosis, essential thrombocythemia and polycythemia vera.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible patients must have myeloproliferative neoplasms, specifically, primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), and PV/ET that are refractory to hydroxyurea, phlebotomy and anagrelide or not a candidate for standard therapies.
- •≥ 18 years of age
- •ECOG performance status of 0-2
- •Acceptable pre-study organ function during screening as defined as:
- •Hematologic:
- •Absolute Neutrophil Count (ANC) ≥1.5x109/L
- •Hemoglobin (Hgb) ≥ 8 g/dl (may be supported with transfusion)
- •Platelets (plt) ≥50x10^9/L
- •Biochemistry:
- •Potassium within normal limits
- •Total calcium (corrected for serum albumin) and phosphorus within normal limits
- •Magnesium above LLN or correctable with supplements Liver and Kidney Functions
- •AST/SGOT and ALT/SGPT ≤ 1.5 x Upper Limit of Normal (ULN) if AP > 2.5 X ULN
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5
- •Serum bilirubin ≤ 1.5 x ULN (Unless attributable to Gilbert's disease)
- •Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 ml/min
- •Negative serum pregnancy test. The serum pregnancy test must be obtained prior to the first administration of AUY922 (≤ 72 hours prior to dosing) in all pre-menopausal women and women <2 years after the onset of menopause
- •Patients who previously received JAK2 inhibitors will be eligible as long as they have been off the drug for more than 4 weeks.
- •Ability to understand and willingness to sign a written informed consent document.
排除标准
- •Requiring ongoing therapy with either G- or GM-CSF, or long-acting versions of these molecules
- •Active medical condition such as infection or cancer that is actively requiring treatment.
- •Unresolved diarrhea ≥ CTCAE (v4.02) grade 1
- •Prior anti-neoplastic treatment with any HSP90 or HDAC inhibitor compound
- •Patients who have undergone any major surgery ≤ 2 weeks prior to starting study drug or have not recovered from the side effects of such therapy.
- •Patient must be ≥ 4 weeks since last chemotherapy or treatment with another systemic anticancer agent with the exception of hydroxyurea. Hydroxyurea must be discontinued at least 48 hours prior to the initiation of AUY
- •Patients must have recovered (CTC ≤ 1) from acute toxicities of any previous therapy (with the exception of alopecia).
- •Active anticoagulation with warfarin.
- •Pregnant or lactating women
- •Fertile women of childbearing potential (WCBP) not using double-barrier methods of contraception (abstinence, oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly, or surgically sterile). Male patients whose partners are WCBP not using double-barrier methods of contraception.
- •Impaired cardiac function, including any one of the following:
- •History (or family history) of long QT syndrome
- •Mean QTc ≥ 450 msec on baseline ECG
- •History of clinically manifested ischemic heart disease (including myocardial infarction, stable or unstable angina pectoris, coronary arteriography or cardiac stress testing/imaging with findings consistent with infarction or clinically significant coronary occlusion) ≤ 6 months prior to study start
- •History of heart failure or left ventricular (LV) dysfunction (LVEF ≤ 45%) by MUGA or ECHO
- •Clinically significant ECG abnormalities including 1 or more of the following: left bundle branch block (LBBB), right bundle branch block (RBBB) with left anterior hemiblock (LAHB). ST segment elevation or depression > 1mm, or 2nd (Mobitz II), or 3rd degree AV block.
- •History or presence of atrial fibrillation, atrial flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de Pointes
- •Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
- •Clinically significant resting bradycardia (< 50 beats per minute)
- •Patients who are currently receiving treatment with any medication which has a relative risk of prolonging the QTcF interval or inducing Torsades de Pointes and cannot be switched or discontinued to an alternative drug prior to commencing AUY
- •Obligate use of a cardiac pacemaker
研究组 & 干预措施
AUY922
Experimental
This is an open-label phase II trial to assess the efficacy of the HSP90 inhibitor, AUY922, in patients with PMF, post-PV MF, post-ET MF, and with PV/ET who are refractory to hydroxyurea, phlebotomy or anagrelide.
干预措施: AUY922 (Drug)
结局指标
主要结局
Overall Objective Response
时间窗: 6 months
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
AUY922 for Advanced ALK-positive NSCLCNon Small Cell Lung CancerNCT01752400Massachusetts General Hospital6
已完成
1 期
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid TumorsMetastatic or Unresectable Solid Tumor MalignancyNCT01226732SCRI Development Innovations, LLC23
终止
2 期
A Study of the HSP90 Inhibitor AUY922LymphomaNCT01485536M.D. Anderson Cancer Center21
已完成
2 期
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal TumorGastrointestinal Stromal TumorNCT01404650SCRI Development Innovations, LLC25
已完成
1 期
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerAdenocarcinoma of the LungNon-small Cell Lung CancerNCT01259089Northwestern University38